Kintara Therapeutics Inc (NAS:KTRA)
$ 7.539 0 (0%) Market Cap: 11.99 Mil Enterprise Value: 17.33 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 24/100

Kintara Therapeutics Inc at Reed Smith Disruptive Growth Conference Transcript

Dec 05, 2022 / 07:40PM GMT
Release Date Price: $296.45 (+10.00%)
Unidentified Participant

-- clinical-stage biopharmaceutical company focused on development and commercialization of new cancer therapies, ticker KTRA. Here to speak upon it is Robert Hoffman, President and CEO.

Robert Hoffman
Kintara Therapeutics, Inc. - President, CEO and Chairman of the Board

Thank you. Appreciate the invite for being here and looking forward to telling you a little bit about why I joined Kintara Therapeutics last year, actually, as CEO.

Before I begin, I'd like to point out will be making numerous forward-looking presentations during this presentation. Actual results may differ, so please refer to the risk factors on file with the SEC.

And again, I'll tell you a little bit about me because lately I've been getting the question, why did you take this job? So, a little bit about me. I joined biotech back in 1997 as the first non-founding employee at Arena Pharmaceuticals. I was there about 17 years, the last 10 years as CFO. I took the company public in 2000, did many transactions -- Eli Lilly, J&J, Merck, different

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot